Invited commentary  by Mills, Joseph L.
Dr Richard Cambria (Boston, Mass). Nice job and an excel-
lent series with excellent results, although I would just caution a bit
in universally adopting your conclusion. Remember, firstly, that
the Eagle criteria and the Annals of Internal Medicine paper that
you showed from 1989 were developed in an era when event rates
were substantially higher than your excellent results. As a matter of
fact, in a previous report from our institution, the patient under-
going infrainguinal bypass surgery was the single highest risk group
for perioperative cardiac event rates. The evolution of events in this
group was often as high as fifteen percent. So your very low event
rate has an impact, obviously, on your results and conclusions.
And secondly, by the time you stratified your groups, you had
relatively small numbers; and a not unsubstantial percentage of
your workup group, in fact, did have a coronary intervention. So
the protective effect of that may explain the equivalent results in
the two groups. I think most vascular surgeons have come around
to the recognition that a patient with a pressing indication for
lower extremity revascularization ought to have that revasculariza-
tion with best medical management of their associated coronary
disease. But I would caution throwing out the whole concept of
cardiac evaluation in patients whose clinical profile clearly indicates
that they need it, irrespective of the timing of an operation.
Dr Monahan. I completely agree with your comments. Pa-
tients whose clinical profile clearly indicated that they needed a
cardiac evaluation were eliminated from our study group; any
patient with a major clinical predictor was not considered in this
study. Likewise patients undergoing emergent operation were not
considered. The patients in this study met inclusion criteria largely
because of their age and diabetes. The weight of these risk factors
as proposed by Dr Eagle is debated amongst cardiologists. We are
challenging the idea that age and diabetes alone should trigger a
preoperative cardiac evaluation.
Additionally, of the ten patients in the work-up group who
had preoperative coronary revascularization, there was one death
in a patient who had had an angioplasty, which occurred at
seventy-six days. The survival of these ten patients at one and two
years was ninety percent at both time points, which by Kaplan-
Meier analysis was not different from the two curves that I pre-
sented earlier. However, obviously, with only ten patients, there is
potential for significant type-two error.
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Coronary artery disease (CAD) commonly lurks in patients
with peripheral arterial disease (PAD), and the more severe the
PAD the worse the CAD. Patients with unstable coronary syn-
dromes, uncompensated congestive heart failure (CHF), uncon-
trolled arrhythmias, and severe valve disease (major predictors)
require cardiac evaluation, regardless of whether a peripheral inter-
vention is on the horizon. Absent major predictors, patients who
require infrainguinal bypass to treat limb-threatening ischemia still
constitute a group at high risk. The clinical conundrum remains: to
what extent does one evaluate cardiac risk in patients who require
infrainguinal bypass or, for that matter, any other peripheral arte-
rial reconstruction?
The Deaconess group, with longstanding expertise in limb
salvage surgery, takes issue with the “ACC/AHA Guideline on
Perioperative Cardiovascular Evaluation for Noncardiac Surgery.”
This document, based on expert, well-meaning opinion, but pre-
cious little hard evidence, suggests that all peripheral arterial oper-
ations are “high risk” and that at least preoperative noninvasive
cardiac testing is required in such patients in the presence of
intermediate predictors, such as mild angina pectoris, previous
myocardial infarction, previous or compensated CHF, renal insuf-
ficiency, or diabetes mellitus.
The authors report a retrospective, nonrandomized study of
140 patients with diabetes undergoing infrainguinal bypass. Car-
diac evaluation was performed at the discretion of the attending
surgeon: 79 patients receiving cardiac evaluation constituted the
workup group, and 61 patients underwent leg bypass with no
cardiac workup. There was no difference in postoperative cardiac
morbidity between the workup and no cardiac workup groups, and
patient survival at 1, 12, and 24 months was identical. The authors
conclude that mandatory preoperative cardiac evaluation, at least
in patients with diabetes who require leg bypass, is unnecessary.
There are problems with the study. It is subject to type II
errors because of small sample size and low event rate, and there is
likely selection bias, inasmuch as significantly more patients in the
workup group had a history of CAD, previous MI, or CHF.
Nevertheless, I suspect the authors are correct. Noninvasive car-
diac testing is flawed by low positive predictive value, and may lead
to unwarranted interventions, such as percutaneous transluminal
coronary angioplasty or coronary bypass, which have not been
scientifically demonstrated to reduce MI or cardiac mortality in
patients with PAD. There is, however, level I evidence that
-blockade is an effective strategy, even in patients at high-risk.1
I suspect that the era of routine preoperative cardiac testing is
at an end, because of its high cost and entirely unproved benefit on
outcomes. We should routinely prescribe -blockade, and perhaps
also statin agents and angiotensin converting enzyme inhibitors in
selected patients, and optimize medical management, and reserve
detailed cardiac testing for patients with major predictors that
warrant cardiac evaluation independent of the need for PAD
intervention.
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